Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.

Xi ChenLiangjie FangYanping ZhuZhang BaoQing WangRong LiuWenjia SunHaiwei DuJing LinBing YuSongan ChenJianya ZhouJianying Zhou

Published in: Cancer immunology, immunotherapy : CII (2021)

Our study confirmed the feasibility of using large panels to estimate TMB. We also demonstrated that bTMB can serve as a potential biomarker for predicting the efficacy of ICIs in NSCLC.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
epidermal growth factor receptor
ejection fraction
chronic kidney disease
newly diagnosed
small cell lung cancer
prognostic factors